The aim of this study is to evaluate whether the addition of amantadine to the management
regimen of traumatic brain injury patients would have a favorable effect on recovery and
neurological complications in association with prognosis biomarkers Interleukin-18 (IL-18),
Neuron-specific enolase (NSE) and (Neurotensin).